Background: The prevalence of carpal tunnel syndrome (CTS) and of anxiety and depression in primary care practice are high. Different studies had shown an increased prevalence of anxiety and depression in CTS patients...Background: The prevalence of carpal tunnel syndrome (CTS) and of anxiety and depression in primary care practice are high. Different studies had shown an increased prevalence of anxiety and depression in CTS patients. Nevertheless, few papers had been published studying the anxiety and depression scales in the treatment of CTS, either with corticosteroid injections (I) or with surgical decompression (S). Objective: To assess whether clinical improvement observed after the treatment of CTS either with I or with S correlates with an improvement in the punctuations of the Hospital Anxiety and Depression scales (HADS), at 3, 6 and 12-month follow-up. Methods: Randomized and open-label clinical trial, comparing I and S. Patients with symptoms suggestive of CTS (nocturnal paraesthesias) of at least 3 months duration and neurophysiological confirmation were included. Patients with clinically apparent motor impairment were excluded. The subjective evaluation of symptoms was carried out using the visual-analogue scale of pain (VAS-p). Clinical reviews were performed 3, 6 and 12 months after treatment. Each patient completed the HADS questionnaire and a VAS-p at 0, 3, 6, and 12 months. Statistical significance was established using the Student’s t test and the Mann-Whitney U test when necessary. A linear regression analysis was used to know the effect of the treatment adjusted for the initial score of both scales. Results: 65 patients were included (30 in group I and 35 in group S). There was no statistical difference between both groups in terms of age, gender distribution, disease duration, VAS-p, neurophysiological testing severity of CTS or the 8 subscales of HADS. Both groups improved significantly in relation to the baseline VAS-p values, in the reviews at 3, 6 and 12 months, with no significant differences between I and S. At 6 months, the reduction in the anxiety scale was around 3 points for both treatments (S = 3.6 and I = 3.2), without reaching significant differences. At 12 months, it was somewhat higher for those treated with I, but always around 3 points and without significant differences. The Depression scale score was slightly reduced at 6 months, and in a similar way for both groups (I = 1 and S = 1.19;p = 0.8). After 12 months, group I doubled the previous reduction, with group S experiencing a very slight change (I = 1.96 and S = 1.03;p = 0.3). When analysing the effect of group S on group I, the result was a reduction of 0.25 points for Anxiety (p = 0.7) and of 0.02 points for Depression (p = 0.9). Conclusions: Treatment of CTS with I or S results in a similar and discrete improvement in Anxiety scores on the HADS scale at 6 and 12 months. For both types of treatment, the Depression scores barely changed at 6 months, being somewhat higher in group I after 12-month follow-up. The independent effect of the S on both scales is small and not significant.展开更多
Prostate cancer is one of the most common types of cancer in men. The rate of early detection of prostate cancer is low in Türkiye. Therefore, it is important to measure the level of awareness regarding prostate ...Prostate cancer is one of the most common types of cancer in men. The rate of early detection of prostate cancer is low in Türkiye. Therefore, it is important to measure the level of awareness regarding prostate cancer. In our research, we investigate the knowledge levels of prostate cancer among adult individuals in four different geographic region in Türkiye. In addition, we aimed to compare the level of awareness regarding prostate cancer and the depression and anxiety levels among the individuals. The prostate cancer awareness level survey was selected as the data collection tool. In the survey, 20 questions are asked to measure the knowledge level of the participants about prostate cancer. In addition, an evaluation of anxiety and depression was conducted by using the Hospital Anxiety and Depression Scale (HADS). Between April 2022 and December 2022, 834 participants were reached.72.9% of the participants answered the questionnaire correctly. A significant difference was found in terms of correct response rates in four different provinces located in four different regions of Türkiye (79% in Eskisehir, 75.2% in Canakkale, 73% in Ankara, and 54.4% in Maras;p < 0.05). According to the HADS scale, 240 (28.8%) individuals were found to have anxiety and 129 (15.5%) of them had depression. The knowledge level of most of the participants about prostate cancer was found to be above the average. There was a significant difference between provinces in terms of knowledge levels. A significant relationship was observed between depression and knowledge level. However, no significant difference was found for anxiety.展开更多
Objectives: The term TMD refers to a group of disorders characterized by pain in the temporomandibular joint and associated structures. The aim of this study was designed to evaluate prevalence, severity and sex distr...Objectives: The term TMD refers to a group of disorders characterized by pain in the temporomandibular joint and associated structures. The aim of this study was designed to evaluate prevalence, severity and sex distribution of sign and symptoms of TMD and to evaluate their relation with anxiety and depression among the students. Material and Methods: A total of 1000 university students were enrolled in the study (550 females;450 males), with ages ranged between 18 and 28 years. Helkimo anamnestic index (Ai) and clinical dysfunction index (Di) were used to determine symptoms and signs respectively. For the association of TMD with anxiety and depression, HAD (Hospital Anxiety and Depression) scale was used. Results showed that prevalence of one or more symptoms of TMD was 27.7%, while the prevalence of one or more signs of TMD was 64.4% which was mild in severity. Mild anamnestic symptoms (AiI) were found in 19.8% and severe symptoms (AiII) were found in 7.6%, while mild clinical sign (DiI), moderate clinical (DiII) and severe clinical sign (DiIII) were found in 49.7%, 12.2% and 2.4% respectively. Statistically there was no gender difference in these two scales. Regarding the association between TMD with anxiety and depression, 206 of the 311 students (66.2%) with TMD symptoms also had signs of anxiety and depression (P < 0.001). Conclusion: These findings confirmed that students had high prevalence of TMD which was significantly associated with anxiety and depression.展开更多
<strong>Background</strong><span style="font-family:Verdana;"> <strong>:</strong></span><span style="font-family:Verdana;">Anxiety and depression are two c...<strong>Background</strong><span style="font-family:Verdana;"> <strong>:</strong></span><span style="font-family:Verdana;">Anxiety and depression are two common psychiatric conditions encountered in cancer treatment. Prevalence rate and risk factors show wide variations in different countries and the environment. COVID 19 outbreak has increased psychological disorders in general public and health workers. Whether this pandemic has increased the psychiatric morbidity in cancer patients need</span><span style="font-family:Verdana;">s</span><span style="font-family:""><span style="font-family:Verdana;"> to be addressed for planning strategies. </span><b><span style="font-family:Verdana;">Methods</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">This cross-sectional study was conducted in the Department of Radiation Oncology, a tertiary cancer centre in the state of Kerala, India. The aim was to assess hospital prevalence and risk factors of anxiety and depression among cancer patients during COVID 19 pandemic. Patients on treatment for cancer and willing for the study were recruited. Hospital Anxiety and Depression Scale (HADS)</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> a self-assessment valid tool for screening both anxiety (HADS-A) and depression (HADS-D) are used. HADS-A &</span><span style="font-family:""> </span><span style="font-family:Verdana;">D were calculated separately & categorized as normal, borderline and abnormal with a score of 0</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">7, 8</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">10 & 11</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">21 respectively. Separate structured questionnaire for COVID19 related questions and patient master file for patient</span><span style="font-family:""> </span><span style="font-family:""><span style="font-family:Verdana;">& treatment characteristics were used in risk assessment. Data were entered in an Excel sheet and SPSS version 22 for statistical analysis. </span><b><span style="font-family:Verdana;">Findings</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">208 patients were included in this study. The overall prevalence rate of anxiety was 7</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">2%, with borderline cases 4</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">3% and abnormal cases 2</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">9%. The overall prevalence of the rate of depression was 5</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">3% (3</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">4% borderline & 1</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">9% abnormal). Risk factors like age, sex, socioeconomic status, primary site, stage of the disease and default of disease had no statistical significance.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Interpretation</span></b><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">The prevalence rate of anxiety and depression among cancer patients in this study is one among the lowest ever reported. COVID 19 outbreak has not brought any impact in the rate of psychological distress in our patients and the low rate may be due to the robust medical care including mental health interventions and reassurance by the Government.</span>展开更多
文摘Background: The prevalence of carpal tunnel syndrome (CTS) and of anxiety and depression in primary care practice are high. Different studies had shown an increased prevalence of anxiety and depression in CTS patients. Nevertheless, few papers had been published studying the anxiety and depression scales in the treatment of CTS, either with corticosteroid injections (I) or with surgical decompression (S). Objective: To assess whether clinical improvement observed after the treatment of CTS either with I or with S correlates with an improvement in the punctuations of the Hospital Anxiety and Depression scales (HADS), at 3, 6 and 12-month follow-up. Methods: Randomized and open-label clinical trial, comparing I and S. Patients with symptoms suggestive of CTS (nocturnal paraesthesias) of at least 3 months duration and neurophysiological confirmation were included. Patients with clinically apparent motor impairment were excluded. The subjective evaluation of symptoms was carried out using the visual-analogue scale of pain (VAS-p). Clinical reviews were performed 3, 6 and 12 months after treatment. Each patient completed the HADS questionnaire and a VAS-p at 0, 3, 6, and 12 months. Statistical significance was established using the Student’s t test and the Mann-Whitney U test when necessary. A linear regression analysis was used to know the effect of the treatment adjusted for the initial score of both scales. Results: 65 patients were included (30 in group I and 35 in group S). There was no statistical difference between both groups in terms of age, gender distribution, disease duration, VAS-p, neurophysiological testing severity of CTS or the 8 subscales of HADS. Both groups improved significantly in relation to the baseline VAS-p values, in the reviews at 3, 6 and 12 months, with no significant differences between I and S. At 6 months, the reduction in the anxiety scale was around 3 points for both treatments (S = 3.6 and I = 3.2), without reaching significant differences. At 12 months, it was somewhat higher for those treated with I, but always around 3 points and without significant differences. The Depression scale score was slightly reduced at 6 months, and in a similar way for both groups (I = 1 and S = 1.19;p = 0.8). After 12 months, group I doubled the previous reduction, with group S experiencing a very slight change (I = 1.96 and S = 1.03;p = 0.3). When analysing the effect of group S on group I, the result was a reduction of 0.25 points for Anxiety (p = 0.7) and of 0.02 points for Depression (p = 0.9). Conclusions: Treatment of CTS with I or S results in a similar and discrete improvement in Anxiety scores on the HADS scale at 6 and 12 months. For both types of treatment, the Depression scores barely changed at 6 months, being somewhat higher in group I after 12-month follow-up. The independent effect of the S on both scales is small and not significant.
文摘Prostate cancer is one of the most common types of cancer in men. The rate of early detection of prostate cancer is low in Türkiye. Therefore, it is important to measure the level of awareness regarding prostate cancer. In our research, we investigate the knowledge levels of prostate cancer among adult individuals in four different geographic region in Türkiye. In addition, we aimed to compare the level of awareness regarding prostate cancer and the depression and anxiety levels among the individuals. The prostate cancer awareness level survey was selected as the data collection tool. In the survey, 20 questions are asked to measure the knowledge level of the participants about prostate cancer. In addition, an evaluation of anxiety and depression was conducted by using the Hospital Anxiety and Depression Scale (HADS). Between April 2022 and December 2022, 834 participants were reached.72.9% of the participants answered the questionnaire correctly. A significant difference was found in terms of correct response rates in four different provinces located in four different regions of Türkiye (79% in Eskisehir, 75.2% in Canakkale, 73% in Ankara, and 54.4% in Maras;p < 0.05). According to the HADS scale, 240 (28.8%) individuals were found to have anxiety and 129 (15.5%) of them had depression. The knowledge level of most of the participants about prostate cancer was found to be above the average. There was a significant difference between provinces in terms of knowledge levels. A significant relationship was observed between depression and knowledge level. However, no significant difference was found for anxiety.
文摘Objectives: The term TMD refers to a group of disorders characterized by pain in the temporomandibular joint and associated structures. The aim of this study was designed to evaluate prevalence, severity and sex distribution of sign and symptoms of TMD and to evaluate their relation with anxiety and depression among the students. Material and Methods: A total of 1000 university students were enrolled in the study (550 females;450 males), with ages ranged between 18 and 28 years. Helkimo anamnestic index (Ai) and clinical dysfunction index (Di) were used to determine symptoms and signs respectively. For the association of TMD with anxiety and depression, HAD (Hospital Anxiety and Depression) scale was used. Results showed that prevalence of one or more symptoms of TMD was 27.7%, while the prevalence of one or more signs of TMD was 64.4% which was mild in severity. Mild anamnestic symptoms (AiI) were found in 19.8% and severe symptoms (AiII) were found in 7.6%, while mild clinical sign (DiI), moderate clinical (DiII) and severe clinical sign (DiIII) were found in 49.7%, 12.2% and 2.4% respectively. Statistically there was no gender difference in these two scales. Regarding the association between TMD with anxiety and depression, 206 of the 311 students (66.2%) with TMD symptoms also had signs of anxiety and depression (P < 0.001). Conclusion: These findings confirmed that students had high prevalence of TMD which was significantly associated with anxiety and depression.
文摘<strong>Background</strong><span style="font-family:Verdana;"> <strong>:</strong></span><span style="font-family:Verdana;">Anxiety and depression are two common psychiatric conditions encountered in cancer treatment. Prevalence rate and risk factors show wide variations in different countries and the environment. COVID 19 outbreak has increased psychological disorders in general public and health workers. Whether this pandemic has increased the psychiatric morbidity in cancer patients need</span><span style="font-family:Verdana;">s</span><span style="font-family:""><span style="font-family:Verdana;"> to be addressed for planning strategies. </span><b><span style="font-family:Verdana;">Methods</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">This cross-sectional study was conducted in the Department of Radiation Oncology, a tertiary cancer centre in the state of Kerala, India. The aim was to assess hospital prevalence and risk factors of anxiety and depression among cancer patients during COVID 19 pandemic. Patients on treatment for cancer and willing for the study were recruited. Hospital Anxiety and Depression Scale (HADS)</span><span style="font-family:Verdana;">,</span><span style="font-family:Verdana;"> a self-assessment valid tool for screening both anxiety (HADS-A) and depression (HADS-D) are used. HADS-A &</span><span style="font-family:""> </span><span style="font-family:Verdana;">D were calculated separately & categorized as normal, borderline and abnormal with a score of 0</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">7, 8</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">10 & 11</span><span style="font-family:""> </span><span style="font-family:Verdana;">-</span><span style="font-family:""> </span><span style="font-family:Verdana;">21 respectively. Separate structured questionnaire for COVID19 related questions and patient master file for patient</span><span style="font-family:""> </span><span style="font-family:""><span style="font-family:Verdana;">& treatment characteristics were used in risk assessment. Data were entered in an Excel sheet and SPSS version 22 for statistical analysis. </span><b><span style="font-family:Verdana;">Findings</span></b></span><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">208 patients were included in this study. The overall prevalence rate of anxiety was 7</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">2%, with borderline cases 4</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">3% and abnormal cases 2</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">9%. The overall prevalence of the rate of depression was 5</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">3% (3</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">4% borderline & 1</span><span style="font-family:Verdana;">.</span><span style="font-family:Verdana;">9% abnormal). Risk factors like age, sex, socioeconomic status, primary site, stage of the disease and default of disease had no statistical significance.</span><span style="font-family:""> </span><b><span style="font-family:Verdana;">Interpretation</span></b><b><span style="font-family:Verdana;">: </span></b><span style="font-family:Verdana;">The prevalence rate of anxiety and depression among cancer patients in this study is one among the lowest ever reported. COVID 19 outbreak has not brought any impact in the rate of psychological distress in our patients and the low rate may be due to the robust medical care including mental health interventions and reassurance by the Government.</span>
